Inactive Ingredient Search for Approved Drug Products

• Share
• Tweet
• Linkedin
• Pin it
• More sharing options
  • Linkedin
  • Pin it
• Email
• Print

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with O

	Quarter	Inactive Ingredient	Route of Administration	Dosage Form	Maximum Potency per unit dose	Maximum Daily Exposure	Status
5607	Q3 2021	OPADRY YS-1-8325 BEIGE	ORAL	TABLET		48 mg	Correction
5607	Q4 2021	OPADRY YS-1-8325 BEIGE	ORAL	TABLET	16.00 mg		Correction
5003	Q3 2021	OLEIC ACID	ORAL	TABLET, EXTENDED RELEASE	2.00 mg		MDE Replacement
5003	Q4 2021	OLEIC ACID	ORAL	TABLET, EXTENDED RELEASE		2.95 mg	MDE Replacement
5007	Q3 2021	OLEIC ACID	TOPICAL	GEL, METERED	2.50 %w/w		MDE Replacement
5007	Q4 2021	OLEIC ACID	TOPICAL	GEL, METERED		87.5 mg	MDE Replacement
5127	Q3 2021	OPADRY 03B58902 WHITE	ORAL	TABLET	10.50 mg		MDE Replacement
5127	Q4 2021	OPADRY 03B58902 WHITE	ORAL	TABLET		21 mg	MDE Replacement
5136	Q3 2021	OPADRY 03F14895 PINK	ORAL	TABLET, FILM COATED	4.00 mg		MDE Replacement
5136	Q4 2021	OPADRY 03F14895 PINK	ORAL	TABLET, FILM COATED		8 mg	MDE Replacement
5139	Q3 2021	OPADRY 03F59016 CLEAR	ORAL	TABLET, EXTENDED RELEASE	4.00 mg		MDE Replacement
5139	Q4 2021	OPADRY 03F59016 CLEAR	ORAL	TABLET, EXTENDED RELEASE		8 mg	MDE Replacement
5185	Q3 2021	OPADRY AMB 80W68912 WHITE	ORAL	TABLET, EXTENDED RELEASE	36.00 mg		MDE Replacement
5185	Q4 2021	OPADRY AMB 80W68912 WHITE	ORAL	TABLET, EXTENDED RELEASE		72 mg	MDE Replacement
5186	Q3 2021	OPADRY AMB 80W68912 WHITE	ORAL	TABLET, FILM COATED	18.00 mg		MDE Replacement
5186	Q4 2021	OPADRY AMB 80W68912 WHITE	ORAL	TABLET, FILM COATED		18 mg	MDE Replacement
5207	Q3 2021	OPADRY II 33G28707 WHITE	ORAL	TABLET, EXTENDED RELEASE	30.00 mg		MDE Replacement
5207	Q4 2021	OPADRY II 33G28707 WHITE	ORAL	TABLET, EXTENDED RELEASE		60 mg	MDE Replacement
5221	Q3 2021	OPADRY II 49B10882 BLUE	ORAL	TABLET	26.90 mg		MDE Replacement
5221	Q4 2021	OPADRY II 49B10882 BLUE	ORAL	TABLET		53.8 mg	MDE Replacement
5236	Q3 2021	OPADRY II 85F18422 WHITE	ORAL	TABLET, EXTENDED RELEASE	51.30 mg		MDE Replacement
5236	Q4 2021	OPADRY II 85F18422 WHITE	ORAL	TABLET, EXTENDED RELEASE		72 mg	MDE Replacement
5345	Q3 2021	OPADRY OY-58900 WHITE	ORAL	TABLET	31.80 mg		MDE Replacement
5345	Q4 2021	OPADRY OY-58900 WHITE	ORAL	TABLET		132 mg	MDE Replacement
5346	Q3 2021	OPADRY OY-58900 WHITE	ORAL	TABLET, FILM COATED	16.25 mg		MDE Replacement
5346	Q4 2021	OPADRY OY-58900 WHITE	ORAL	TABLET, FILM COATED		65 mg	MDE Replacement
5410	Q3 2021	OPADRY Y-5-7068 WHITE	ORAL	TABLET	120.00 mg		MDE Replacement
5410	Q4 2021	OPADRY Y-5-7068 WHITE	ORAL	TABLET		290.25 mg	MDE Replacement
5559	Q3 2021	OPADRY YS-1-7003 WHITE	ORAL	TABLET	147.80 mg		MDE Replacement
5559	Q4 2021	OPADRY YS-1-7003 WHITE	ORAL	TABLET		402.84 mg	MDE Replacement
5571	Q3 2021	OPADRY YS-1-7006 CLEAR	ORAL	TABLET	56.05 mg		MDE Replacement
5571	Q4 2021	OPADRY YS-1-7006 CLEAR	ORAL	TABLET		111.24 mg	MDE Replacement
5590	Q3 2021	OPADRY YS-1-7472 CLEAR	ORAL	CAPSULE, EXTENDED RELEASE	50.76 mg		MDE Replacement
5590	Q4 2021	OPADRY YS-1-7472 CLEAR	ORAL	CAPSULE, EXTENDED RELEASE		50.76 mg	MDE Replacement
5611	Q3 2021	OPADRY YS-1R-7006 CLEAR	ORAL	TABLET	26.25 mg		MDE Replacement
5611	Q4 2021	OPADRY YS-1R-7006 CLEAR	ORAL	TABLET		37.54 mg	MDE Replacement
5459	Q4 2021	OPADRY YS-1-14142 PINK	ORAL	TABLET, FILM COATED, EXTENDED RELEASE	16.00 mg	26.8 mg	Deletion
5616	Q4 2021	OPADRY YS-2-19114A CLEAR	ORAL	TABLET, EXTENDED RELEASE	1.50 mg		Deletion
5645	Q4 2021	OPALUX AS 2553 ORANGE	ORAL	TABLET	NA		Deletion
5654	Q4 2021	OPALUX AS 5034 RED	ORAL	TABLET, COATED	0.02 mg		Deletion

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: September 30, 2021
Database Last Updated: October 21, 2021